June 22, 2025

TFOS Completes DEWS III

Updates on recommendations & conclusions of TFOS DEWS II.

Contact Lens Spectrum

June 17, 2025

Aldeyra Therapeutics Resubmits Reproxalap NDA for the Treatment of DED

Per FDA agreement, the only new clinical data included in the resubmitted new drug application were from the recently completed dry eye chamber trial, which achieved the primary endpoint, according to the company.

Ophthalmology Management

May 08, 2025

Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 DED Chamber Trial of Reproxalap

In a dry eye chamber trial, Reproxalap was statistically superior (P = .002) to vehicle in primary endpoint of ocular discomfort.

Ophthalmology Management

July 01, 2023

BUSINESS Coding Strategy

PentaVision is an independent company dedicated to eye care professionals. More about our magazines, newsletters, conferences, education and other services at pentavisionmedia.com.

Optometric Management

April 01, 2023

THE BUSINESS OF CONTACT LENSES

PentaVision is an independent company dedicated to eye care professionals. More about our magazines, newsletters, conferences, education and other services at pentavisionmedia.com.

Contact Lens Spectrum

February 01, 2023

THE STATE OF SCLERAL LENS PRESCRIBING

PentaVision is an independent company dedicated to eye care professionals. More about our magazines, newsletters, conferences, education and other services at pentavisionmedia.com.

Contact Lens Spectrum

March 01, 2023

DOES SCLERAL LENS WEAR IMPACT MGD?

PentaVision is an independent company dedicated to eye care professionals. More about our magazines, newsletters, conferences, education and other services at pentavisionmedia.com.

Contact Lens Spectrum

January 16, 2025

LA County Fires Prompt Business Recovery Centers to Open

"Business owners can meet face-to-face with specialists to apply for disaster loans and access a wide range of resources to guide them through their recovery."

Optometric Management

November 01, 2024

DRY EYE: Parting wisdom

For the last four years, I’ve had the privilege of using this column as a platform to share insights and advice on ocular surface disease. It has been an eye-opening experience; one that has allowed me to connect with colleagues.

Optometric Management